SAB Biotherapeutics, Inc.

NASDAQ:SABS

Biotechnology

Healthcare
$3.20 -0.53%

-$0.02 today

Market cap
$288.28M
Beta
0.53
P/E (TTM)
3.0
EPS (TTM)
-$0.16
52W Low $1.85High $5.15

Volume 0.89M

Average 0.76M

SABS Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

SAB Biotherapeutics, Inc.NASDAQ: SABS

Net Change in Cash · Q2 FY2026 · quarter ended Jun 2026

Net change in cash grows, but more slowly than its trailing trend

Q2 FY2026 net change in cash of $2.24M (cash outflow) rose 14.8% year over year, behind the +207.7% change in trailing-twelve-month net change in cash.

Context

  • Net change in cash increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +14.8% toward the trailing-twelve-month pace of +207.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$2.24M-122.3% QoQ
Last fiscal yearDec 2025
$1.6M+103.4% YoY
LTMJun 2026
$14.59M+207.7% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.8%——
1 year+103.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
1.6M USD
Year-over-year change
+103.4%
4-year CAGR
-50.6%

Net Change in Cash vs competitors

How SABS compares with its peers on the latest reported figures

  • SABS's LTM Jun 2026 net change in cash of $14.59M is the 3rd largest of the 5 companies compared; the peer median is $3.31M.
  • Its year-over-year change of +207.7% is the 2nd highest of 5, against a peer median of +35.0%.
SABS Competitors Peer median
Net Change in Cash for SABS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$33.5M +811.6%——
QTTBQ32 Bio Inc.LTM Mar 2026$14.73M -70.6%—27.4%
SABSSAB Biotherapeutics, Inc.LTM Jun 2026$14.59M +207.7%——
VRCAVerrica Pharmaceuticals Inc.LTM Mar 2026$9M -53.5%—24.2%
BOLDBoundless Bio, Inc.LTM Mar 2026$2.37M +123.6%-28.0%—
Peer median (excluding SABS) $3.31M+35.0%-28.0%25.8%

Competitors are the stored peer set for SABS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(17.14M)(18.74M)(42.19M)(34.11M)13.27M
Depreciation & Amortization1.65M3.29M3.75M4.79M3.08M
Deferred Income Tax00000
Stock-Based Compensation2.31M2.67M2.42M2.94M5.21M
Change in Working Capital11.68M(237.58K)2.33M(2.3M)(3.69M)
Accounts Receivables12.56M2.45M5.56M(54.96K)(891.83K)
Inventory00000
Accounts Payables(2.94M)(779.43K)(2.7M)923.32K1.48M
Other Working Capital2.06M(1.91M)(528.64K)(3.17M)(4.28M)
Other Non-Cash Items3.48M(10.45M)8.58M(5.62M)(62.66M)
Operating Cash Flow1.99M(23.46M)(25.12M)(34.29M)(44.78M)
Capital Expenditures(10.94M)(2.17M)(197.15K)(337.26K)(933.15K)
Acquisitions (Net)0000500
Purchases of Investments000(37.45M)(142.04M)
Sales of Investments00025.82M21.26M
Other Investing Activities076.39K44.45K00
Investing Cash Flow(10.94M)(2.09M)(152.7K)(11.96M)(121.71M)
Debt Repayment1.54M(1.19M)(390.45K)(907K)(418.41K)
Common Stock Issued6.75K7.68M020.41K168.73M
Common Stock Repurchased0(5.52M)000
Dividends Paid00000
Other Financing Activities34.34M76.97K59.66M(286.04K)(11.96K)
Financing Cash Flow35.89M1.05M66.77M(1.17M)168.3M
Effect of Forex Changes0018.14K(241.2K)(213.5K)
Net Change in Cash26.93M(24.5M)41.52M(47.67M)1.6M
Free Cash Flow(8.96M)(25.63M)(25.32M)(34.63M)(45.71M)

SAB Biotherapeutics, Inc.

NASDAQ:SABS

Intrinsic Alpha fair value

Locked

Current Price

$3.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.